© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
October 27, 2019
Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis and the only approved therapy shown to shrink nasal polyp size and improve the signs and symptoms of the associated chronic rhinosinusitis.
With a resurgence in vaccine-preventable diseases, it is incumbent upon pharmacists to take a lead role in providing education on the importance of vaccines in protecting public health.